Malaysian company acquires SSI vaccine production business
Bech-Bruun assisted Malaysian AJ Pharma's subsidiary, AJ Biologics, in its acquisition of Statens Serum Institut's (SSI's) vaccine production business.
AJ Pharma makes its first acquisition in Denmark, creating a new entity from the SSI vaccine production business through its subsidiary, AJ Biologics. This will open new avenues for growth and employment for the Danish business and expansion at a global level.
The SSI vaccine production business has its facility in Copenhagen, Denmark, and is a distinct business unit of Statens Serum Institut, a public enterprise under the Danish Ministry of Health. The transaction will make SSI's vaccine production business an independent, privately held entity with improved opportunities for growth and employment.
Dr Tabassum Khan, Managing Director of AJ Pharma Holding and Chairman of AJ Biologics, says:
"We are impressed by the vaccine portfolio and manufacturing expertise that SSI has built over the years and with its heritage and positioning at the core of public health across many countries. Further to our analysis, supported by our advisors, including NNE Pharmaplan, Bech-Bruun and KPMG, we see significant opportunities for growth acceleration, as well as partnerships and business synergies."
Bech-Bruun advised AJ Pharma throughout the entire process. AJ Pharma is the healthcare investment arm of Aljomiah Group, founded back in 1936 and today one of the top conglomerates in the Kingdom of Saudi Arabia.
The transaction is expected to close by the end of 2016.